

Regulatory Announcement

[Go to market news section](#)



Company	Omega Diagnostics Group PLC
TIDM	ODX
Headline	European patent grant
Released	07:00 06-Nov-06
Number	5162L



Omega Diagnostics Group PLC

European patent grant

Omega Diagnostics Group PLC is pleased to announce that a European Patent (0994121) has been granted in respect of its Branched Peptide technology which has been exclusively licensed from the Medical Research Council (MRC). The Patent covers the enabling technology that allows assays to be developed with resulting superior sensitivity and specificity, which are key features of any new diagnostic test. The technology is currently being applied to a new test for Herpes Simplex Virus 2 (HSV-2) and it has already shown to be effective in increasing the efficacy of other tests such as Human Immunodeficiency Virus (HIV)

In addition to the grant of the Branched Peptide Patent in Europe, a US Patent (5,965,357) has already been granted in respect of the specific peptide sequence for HSV-2 which means that the intellectual property aspect of this development is well covered for the future.

HSV is a chronic disease that infects over 1 billion people worldwide. It is also estimated that there are over 60 million adults in the US infected with HSV-2 and because HSV-2 is difficult to diagnose, the need for more accurate diagnosis is acute.

END

[Close](#)

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

©2007 London Stock Exchange plc. All rights reserved